All 2 tracked stories fall under one category: pharma. Apogee Therapeutics is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 23-day window averages about 0.6 stories each week. At 5, the average consequence score sits below the same-window beat average of 6.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Xponential Fitness
All 2 tracked stories fall under one category: pharma. Apogee Therapeutics is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 23-day window averages about 0.6 stories each week. At 5, the average consequence score sits below the same-window beat average of 6. Each story carries 3.5 original sources on average, compared with 3.5 for the broader beat in this window. This profile follows 2 Biotech stories mentioning Xponential Fitness across the period from February 25, 2026 to March 19, 2026.
Stories tracked
2
Per week
0.6
Sources per story
3.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 295 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Xponential Fitness. Shared-story counts are live from our verified record — not editorial picks.
Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Viatris (VTRS) and CRA International (CRAI) are scheduled to report Q4 results on February 26, 2026, providing critical insights into the generic drug market and life sciences consulting demand. These reports come as the industry faces significant regulatory and pricing headwinds from the Inflation Reduction Act and a shifting biosimilar landscape.
Xponential Fitness is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.